Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 35.71% | 172.88% | 308.87% | 482.76% | 348.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.71% | 172.88% | 308.87% | 482.76% | 348.16% |
| Cost of Revenue | 4.81% | 26.86% | 64.42% | 131.43% | 112.22% |
| Gross Profit | 59.13% | 569.97% | 4,892.50% | 344,500.00% | 2,830.59% |
| SG&A Expenses | -40.49% | 52.84% | 34.35% | 33.41% | 7.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.82% | 49.96% | 36.82% | 38.58% | 12.44% |
| Operating Income | 53.50% | -27.93% | -10.91% | -13.79% | 4.07% |
| Income Before Tax | -117.04% | -70.74% | -86.63% | -90.10% | 162.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -117.04% | -70.74% | -86.63% | -90.10% | 162.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.04% | -70.74% | -86.63% | -90.10% | 162.65% |
| EBIT | 53.50% | -27.93% | -10.91% | -13.79% | 4.07% |
| EBITDA | 53.90% | -28.19% | -10.69% | -13.32% | 4.78% |
| EPS Basic | -109.09% | -70.00% | -86.67% | -91.67% | 157.89% |
| Normalized Basic EPS | -100.00% | -50.00% | -84.21% | -86.36% | 158.33% |
| EPS Diluted | -133.33% | -100.00% | -100.00% | -105.56% | 109.09% |
| Normalized Diluted EPS | -100.00% | -75.00% | -91.67% | -92.86% | 116.67% |
| Average Basic Shares Outstanding | 1.40% | 2.25% | 3.23% | 3.57% | 3.74% |
| Average Diluted Shares Outstanding | -55.66% | 20.03% | 47.43% | 33.47% | 76.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |